Share on StockTwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Michael A. Zasloff purchased 3,500 shares of Amphastar Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average price of $10.00 per share, for a total transaction of $35,000.00. Following the completion of the purchase, the director now directly owns 17,639 shares in the company, valued at approximately $176,390. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.

Amphastar Pharmaceuticals (NASDAQ:AMPH) traded up 0.70% on Wednesday, hitting $10.08. The stock had a trading volume of 64,044 shares. Amphastar Pharmaceuticals has a 52-week low of $6.67 and a 52-week high of $11.07. The stock’s 50-day moving average is $9.40 and its 200-day moving average is $9.44. The company’s market cap is $437.5 million.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings data on Tuesday, August 12th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.13. Analysts expect that Amphastar Pharmaceuticals will post $-0.17 EPS for the current fiscal year.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.